Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (>= 75) patients

Alkan, Ali; GÜÇ, ZEYNEP; Gurbuz, Mustafa; ozgun, Guliz; Degirmencioglu, Serkan; Dogan, Mutlu; AKIN TELLİ, TUĞBA; KESKİN, ÖZGE; Arslan, Cagatay; Bilgin, Burak; SEZGİN GÖKSU, SEMA; Demir, Hacer; Koksoy, Elif; Kostek, Osman; Erturk, Ismail; ŞAKALAR, Teoman; Yasar, Arzu; Turkkan, Gorkem; Kasim, Bu; KARAOĞLU, AZİZ; oksuzoglu, Berna; Yumuk, Fulden; ŞENDUR, MEHMET; COŞKUN, HASAN; ÇİÇİN, İRFAN; Karadurmu, Nuri; TANRIVERDİ, ÖZGÜR; AKBULUT, HAKAN; ÜRÜN, YÜKSEL

doi:10.31083/jomh.2021.041

Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (>= 75) patients

Atıf İçin Kopyala

Alkan A., GÜÇ Z. G., Gurbuz M., ozgun G., Degirmencioglu S., Dogan M., ...Daha Fazla

JOURNAL OF MENS HEALTH, cilt.17, ss.128-134, 2021 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 17
Basım Tarihi: 2021
Doi Numarası: 10.31083/jomh.2021.041
Dergi Adı: JOURNAL OF MENS HEALTH
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.128-134
Anahtar Kelimeler: Metastatic castration-resistant prostate cancer, Enzalutamide, Abiraterone Acetate, Elderly, CHEMOTHERAPY, DOCETAXEL, SURVIVAL, OUTCOMES, SAFETY, MEN
Erciyes Üniversitesi Adresli: Hayır

Özet

Introduction: The efficacy and tolerability of Enzalutamide and Abiraterone Acetate have been reported in elderly patients with metastatic castration resistant prostate cancer (mCRPC). However, there is no randomized study directly comparing antitumor effects between these 2 agents in geriatric patients. We aimed to evaluate the efficacy of Enzalutamide (ENZA) and Abiraterone Acetate (AA) as a first-line treatment of mCRPC in elderly patients.